Idera Pharmaceuticals Announces Tilsotolimod Updates; Says No Further Enrollment In ILLUMINATE-206 Trial Is Planned At This Point
EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. ("Idera," the "Company," "we," "us," and "our") (NASDAQ:IDRA) today announced clinical updates
21 Stocks Moving in Thursday’s Pre-Market Session
Gainers
Pear Therapeutics, Inc. (NASDAQ: PEAR) rose 64% to $15.20 in pre-market trading after climbing around 16% on Wednesday.
‘5 Penny Stocks To Buy According To Analysts & Targets Up To 341%’ -PennyStocks.com Article Highlighting Idera, Biofrontera, SPI Energy, ReWalk, Arbutus
https://pennystocks.com/featured/2021/12/08/5-penny-stocks-to-buy-according-to-analysts-targets-341/
Idera Pharmaceuticals Q2 EPS $(0.15) Up From $(0.24) YoY
Idera Pharmaceuticals (NASDAQ:IDRA) reported quarterly losses of $(0.15) per share. This is a 37.5 percent increase over losses of $(0.24) per share from the same period last year.
